Kazia Therapeutics (KZIA) Stock Forecast & Price Target

Kazia Therapeutics is supported by a differentiated lead asset in paxalisib, an oral, brain-penetrant PI3K/mTOR inhibitor designed to address the validated PAM pathway across cancers with high unmet need. Early clinical signals are encouraging, including an 83% ORR in a six-patient TNBC cohort and prior GBM data showing mOS of 15.7 months and mPFS of 8.6 months, while favorable tolerability and BBB penetration strengthen the thesis. The broader pipeline adds optionality through planned HR+/HER2- breast cancer and colorectal programs, and partnerships plus milestone income support development with reported YE:26 cash of $71 million and a projected equity value of $668 million.

Kazia Therapeutics is facing a fundamentally high-risk investment case because paxalisib has not yet shown compelling, durable efficacy or a clean tolerability profile in GBM, while the FDA said the existing GBM data were insufficient for accelerated approval and suggested additional evidence. The program is also exposed to a classwide toxicology problem: PI3K/PAM inhibition commonly causes hyperglycemia, stomatitis, diarrhea, and discontinuations, and Kazia’s own data showed frequent dose interruptions and treatment-related adverse events that could cap effective dosing before meaningful pathway suppression is achieved. On top of that, the company remains pre-commercial with no FDA- or EMA-approved products, will likely need another Phase III study, and may require additional financing, leaving shareholders exposed to clinical, regulatory, competitive, and dilution risk.